{"prompt": "['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'ALT >3x ULN and total bilirubin >2x ULN', 'ALT >8x ULN at any time, regardless of total bilirubin or accompanying', 'symptoms', 'ALT >5x ULN for >2 weeks, regardless of total bilirubin or accompanying', 'symptoms. The elevation should be continuous for >2 consecutive weeks. If the', 'level decreases for some time within 2 weeks, subject permanent discontinuation', 'is not mandated, but left under Investigator discretion. Resuming the IMP should', 'be discussed on a case by case basis.', 'ALT >3x ULN, accompanied by symptoms which, as determined by the', 'Investigator, are the result of hepatic injury (e.g., fatigue, nausea, vomiting, right', 'upper quadrant pain or tenderness, fever, rash, eosinophilia [>5%]).', 'Any AE that results in an unplanned hospitalization or prolonged hospitalization should be', 'documented and reported as an SAE. The following hospitalization scenarios are examples', 'of events not considered to be SAEs:', 'Hospitalization for a pre-existing condition, provided that any of the following criteria', 'are met:', '- Routine treatment or monitoring of the studied indication, not associated with any', 'deterioration in condition or', '- Elective or preplanned treatment for a pre-existing condition that is unrelated to', 'the indication under study and has not worsened since the start of study treatment.', 'Treatment on an emergency outpatient basis for an event not fulfilling any of the', 'definitions of an SAE given above and not resulting in hospital admission.', \"Social reasons and respite care in the absence of any deterioration in the subject's\", 'general condition.', 'Any SAEs occurring after a subject has received the last dose of study treatment will be', \"collected and reported to R-Pharm International's designee through the end of the Safety\", 'Follow-Up Period (i.e., for a period of 22 weeks after the last dose of study treatment),', \"regardless of the Investigator's opinion of causality. The Investigator must also inform\", 'participating subjects of the need to inform the Investigator of any SAE that occurs within', 'this period. Any SAE with a start date after the Safety Follow-Up Period is not required to', 'be reported unless the Investigator thinks that the event may be related to either the study', 'treatment, study treatment administration, or a protocol procedure.', 'All deaths that occur during the protocol-specified AE reporting period, regardless of', 'relationship to the study treatment, must be recorded on the SAE page in the eCRF and', 'Amendment 2: 06 March 2019', '100', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', \"immediately reported to R-Pharm International or their's designee. This includes death\", 'attributed to progression of RA.', 'Death should be considered an outcome and not a distinct event. The event or condition that', 'caused or contributed to the fatal outcome should be recorded as the description of event on', 'the SAE page in the eCRF. Generally, only 1 such event leading to death should be reported.', 'The use of the term \"sudden death\" as the description of an event should be used, for', 'example, in case of presence of such cardiovascular diagnosis in the source documents or', 'occurrence of an unexpected cardiac death within scenarios as described in Potential MACE', 'Reporting Site Manual. If the cause of death is unknown and cannot be ascertained at the', 'time of reporting, \"unexplained death\" should be recorded on the SAE page as the', 'description of the event in the eCRF. If the cause of death later becomes available (e.g., after', 'autopsy), \"unexplained death\" should be replaced by the established cause of death.', '7.4.2.1', 'Lack of Efficacy or Worsening of Rheumatoid Arthritis', 'Medical occurrences or symptoms of deterioration that are anticipated as part of RA should', 'be recorded as an AE if judged by the Investigator to have unexpectedly worsened in severity', 'or frequency or changed in nature at any time during the study. When recording an', 'unanticipated worsening of RA on the AEs eCRF page, it is important to convey the concept', 'that the condition has changed by including applicable descriptors (e.g., \"accelerated RA\").', 'Events that are clearly consistent with the expected pattern of progression of the underlying', 'disease, as determined by the Investigator, should not be recorded as AEs; these data will be', 'captured as efficacy assessment data only. Every effort should be made to document', 'progression using objective criteria. If there is any uncertainty as to whether an event is an', 'AE or due to disease progression, it should be reported as an AE.', 'Any worsening of RA that meets the criteria for seriousness should be reported as an SAE.', '7.4.2.2', 'Overdose', 'Study treatment overdose is the accidental or intentional use of the drug in an amount higher', 'than the dose being studied. An overdose or incorrect administration of study treatment is', 'not an AE unless it results in untoward medical effects. Any study treatment overdose or', 'incorrect administration of study treatment should be noted on the Study Drug', 'Administration eCRF. All AEs associated with an overdose or incorrect administration of', 'study treatment should be recorded on the AEs eCRF page.', 'Amendment 2: 06 March 2019', '101', 'Confidential']\n\n###\n\n", "completion": "END"}